Pancreatic cancer is a lethal malignancy in digestive system with obscure early symptoms, rapid progression and hardly early diagnosis. Current treatment is not effective. Therefore, there is an urgent need to develop more effective treatments. As an immunotherapy, cancer vaccine is a treatment in which neoantigens are exogenously given to patients to stimulate antitumor adaptive immune response. Thus, tumor growth could be controlled. Tumor regression could be induced. Residual lesions could be eradicated. Classical cancer vaccines are always combined with adjuvants that activate dendritic cells (DCs) or DCs themselves. The research on tumor vaccines in malignant tumors such as melanoma and lung cancer shows good application prospects. However, relevant researches present little progress in pancreatic cancer. This review summarizes current findings of pancreatic cancer vaccines and makes expectations for its future.